News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
101,574 Results
Type
Article (5769)
Company Profile (13)
Press Release (95792)
Multimedia
Podcasts (15)
Webinars (5)
Section
Business (39517)
Career Advice (360)
Deals (7094)
Drug Delivery (17)
Drug Development (8681)
Employer Resources (29)
FDA (1455)
Job Trends (1782)
News (56234)
Policy (3984)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Standard (1)
Academia (261)
Accelerated approval (6)
Adcomms (1)
Allergies (20)
Alliances (5356)
ALS (22)
Alzheimer's disease (175)
Antibody-drug conjugate (ADC) (62)
Approvals (1467)
Artificial intelligence (71)
Autoimmune disease (32)
Automation (8)
Bankruptcy (66)
Best Places to Work (1447)
BIOSECURE Act (2)
Biosimilars (38)
Biotechnology (14)
Bladder cancer (9)
Brain cancer (6)
Breast cancer (82)
Cancer (558)
Cardiovascular disease (25)
Career advice (322)
Career pathing (4)
CAR-T (39)
CDC (8)
Cell therapy (115)
Cervical cancer (3)
Clinical research (7400)
Collaboration (239)
Company closure (1)
Compensation (53)
Complete response letters (10)
COVID-19 (343)
CRISPR (5)
C-suite (360)
Cystic fibrosis (28)
Data (668)
Denatured (2)
Depression (18)
Diabetes (76)
Diagnostics (827)
Digital health (8)
Diversity, equity & inclusion (10)
Drug discovery (45)
Drug pricing (21)
Drug shortages (5)
Duchenne muscular dystrophy (71)
Earnings (17729)
Editorial (18)
Employer branding (1)
Employer resources (27)
Events (11414)
Executive appointments (432)
FDA (1871)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Funding (261)
Gene editing (22)
Generative AI (5)
Gene therapy (102)
GLP-1 (144)
Government (602)
Grass and pollen (1)
Guidances (79)
Healthcare (2963)
HIV (4)
Huntington's disease (7)
IgA nephropathy (16)
Immunology and inflammation (36)
Immuno-oncology (12)
Indications (11)
Infectious disease (389)
Inflammatory bowel disease (38)
Inflation Reduction Act (1)
Influenza (19)
Intellectual property (57)
Interviews (44)
IPO (3057)
IRA (8)
Job creations (349)
Job search strategy (278)
JPM (4)
Kidney cancer (3)
Labor market (13)
Layoffs (71)
Leadership (7)
Legal (1041)
Liver cancer (8)
Longevity (3)
Lung cancer (74)
Lymphoma (28)
Machine learning (6)
Management (7)
Manufacturing (114)
MASH (35)
Medical device (2124)
Medtech (2140)
Mergers & acquisitions (4349)
Metabolic disorders (182)
Multiple sclerosis (19)
NASH (3)
Neurodegenerative disease (43)
Neuropsychiatric disorders (16)
Neuroscience (363)
NextGen: Class of 2026 (957)
Non-profit (424)
Now hiring (4)
Obesity (76)
Opinion (68)
Ovarian cancer (26)
Pain (36)
Pancreatic cancer (19)
Parkinson's disease (44)
Partnered (2)
Patents (92)
Patient recruitment (67)
Peanut (6)
People (17212)
Pharmaceutical (10)
Pharmacy benefit managers (6)
Phase 1 (2362)
Phase 2 (3463)
Phase 3 (2560)
Pipeline (910)
Policy (46)
Postmarket research (159)
Preclinical (852)
Press Release (17)
Prostate cancer (23)
Psychedelics (9)
Radiopharmaceuticals (70)
Rare diseases (134)
Real estate (546)
Recruiting (15)
Regulatory (2976)
Reports (15)
Research institute (292)
Resumes & cover letters (44)
Rett syndrome (3)
RNA editing (1)
RSV (8)
Schizophrenia (41)
Series A (59)
Series B (29)
Service/supplier (1)
Sickle cell disease (11)
Special edition (3)
Spinal muscular atrophy (19)
Sponsored (9)
Startups (550)
State (1)
Stomach cancer (1)
Supply chain (19)
Tariffs (7)
The Weekly (13)
Vaccines (131)
Venture capital (18)
Weight loss (46)
Women's health (10)
Worklife (2)
Date
Last 7 days (102)
Last 30 days (343)
Last 365 days (4820)
2026 (578)
2025 (4913)
2024 (6063)
2023 (6557)
2022 (9089)
2021 (9318)
2020 (8360)
2019 (6547)
2018 (5123)
2017 (4782)
2016 (4474)
2015 (5165)
2014 (3872)
2013 (2932)
2012 (3197)
2011 (3315)
2010 (2976)
Location
Africa (112)
Alabama (13)
Alaska (2)
Arizona (49)
Arkansas (4)
Asia (6908)
Australia (988)
California (1660)
Canada (672)
China (212)
Colorado (102)
Connecticut (89)
Delaware (48)
Europe (14456)
Florida (284)
Georgia (61)
Idaho (6)
Illinois (132)
India (7)
Indiana (108)
Japan (91)
Kansas (11)
Kentucky (3)
Louisiana (3)
Maine (7)
Maryland (251)
Massachusetts (1120)
Michigan (30)
Minnesota (73)
Missouri (12)
Montana (13)
Nebraska (6)
Nevada (15)
New Hampshire (21)
New Jersey (674)
New Mexico (7)
New York (423)
North Carolina (278)
Northern California (803)
Ohio (49)
Oklahoma (4)
Oregon (2)
Pennsylvania (318)
Puerto Rico (10)
Rhode Island (8)
South America (173)
South Carolina (4)
Southern California (660)
Tennessee (16)
Texas (278)
United States (6094)
Utah (38)
Virginia (21)
Washington D.C. (9)
Washington State (80)
West Virginia (1)
Wisconsin (15)
Wyoming (1)
101,574 Results for "aspen pharmacare holdings".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Funding
Aspen’s $115M Series C Opens Doors to Late-Stage Development for Parkinson’s Program
Aspen is now also considering the possibility of an initial public offering next year in an effort to bring its cell therapy to the market.
November 20, 2025
·
1 min read
·
Tristan Manalac
Press Releases
Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
November 21, 2025
·
4 min read
Press Releases
Aspen Neuroscience Completes Phase 1/2a ASPIRO Trial Cohort Three Dosing and State-of-the-Art Manufacturing Expansion, Paving the Way for Developing Transformative Therapies for Patients
January 9, 2026
·
4 min read
Press Releases
Aspen Neuroscience Appoints Chief Commercial Officer Lisa Johnson-Pratt, M.D. and Welcomes Revati Shreeniwas, M.D., FCCP as Chief Medical Officer to Accelerate Late‑Stage Development and Commercial Readiness
January 8, 2026
·
4 min read
Press Releases
Aspen Neuroscience Initiates Cohort 3 in ASPIRO Phase 1/2a Trial, Highlighting Commercial Formulation of ANPD001 and Its Transformative Potential for Parkinson’s Disease
September 26, 2025
·
4 min read
Press Releases
Dalen Meeter Joins Aspen Neuroscience as Chief Financial Officer
May 1, 2025
·
2 min read
Press Releases
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 6, 2025
·
3 min read
Gene editing
FDA Lifts One of Two Clinical Holds on Intellia’s ATTR Gene Editing Program
After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs for hereditary transthyretin amyloidosis.
January 27, 2026
·
2 min read
·
Dan Samorodnitsky
Press Releases
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
April 25, 2025
·
8 min read
Press Releases
Aspen Neuroscience to Present at the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting
June 9, 2025
·
2 min read
1 of 10,158
Next
